Clinical Trial Detail

NCT ID NCT02899793
Title Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Yale University
Indications

endometrial cancer

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST